CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics

Overview of attention for article published in Cancer Cell International, January 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 6,734 followers.

RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…

RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…

RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…

RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.